Back to Journals » OncoTargets and Therapy » Volume 9

Fundamental effects of PD-1 antibody on the body: a brief report

Authors Wang W, Liu B, Liu G, Guo W

Received 21 January 2016

Accepted for publication 16 May 2016

Published 7 July 2016 Volume 2016:9 Pages 4137—4141


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Triparna Sen

Peer reviewer comments 5

Editor who approved publication: Professor Min Li

Wei Wang,1 Bing Liu,1 Guangxian Liu,1 Wanfeng Guo2

1Cancer Therapy Center, 2Department of Healthcare and Medicine, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, People’s Republic of China

Abstract: We report the case of a 61-year-old man with squamous cell carcinoma of the left lung and mediastinal lymph node metastases who received nivolumab and experienced a better antitumor effect than expected but died soon afterward. A clinical analysis showed that the grades of the treatment-related events did not cause death. The immunological impact of this treatment on his body, especially at his age and with concurrent infection, possibly augmented by the blockade of the PD-1/PD-L1 signaling pathway, is proposed to be one of the key factors for his death. Consequently, we suggest that the cellular immune status and the clinical characteristics of patients, especially the symptoms like concurrent infection, should be considered in the design of clinical protocol of such a kind of therapy.

Keywords: lung cancer, PD-1, nivolumab, immunotherapy, lung infection, immunosuppression

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]